Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
2021-11-09 09:30:01
Oslo (Norway), 9 November 2021 - PCI Biotech (OSE: PCIB), a clinical-stage
biopharma company developing innovative therapeutics that address significant
unmet medical needs in cancer today announced that it will present a poster at
the 9(th) International mRNA Health Conference, a combined on-site and virtual
event taking place November 9-10, 2021 in Berlin, Germany.
Today at 16:45 - 18:30 (CET), Dr. Anders Høgset, CSO, will on-site present a
poster named 'Photochemical internalisation (PCI) - enhanced and site-directed
mRNA delivery by light-induced endosomal release' giving an overview of PCI
Biotech's proprietary platform technology for use in the exciting field of mRNA-
based therapies. Please find the poster enclosed.
Contact information:
Per Walday, CEO
pw@pcibiotech.no (mailto:pw@)
Mobile: +47 917 93 429
About The International mRNA Health Conference
The International mRNA Health Conference is the premier meeting destination for
industry and academic professionals to explore the rapidly advancing science and
business of mRNA medicines. The conference provides participants with a platform
for networking with experts, giving them an opportunity to learn more about
developments in mRNA technology and to see scientific presentations by some of
the most esteemed experts in the field. The event brings together over 650
attendees from leading pharma and biotech companies as well as academic
institutions.
About PCI Biotech
PCI Biotech is a biopharmaceutical late-stage clinical development company
focusing on development and commercialisation of novel therapies for the
treatment of cancer through its innovative photochemical internalisation (PCI)
technology platform. PCI is applied to three distinct anticancer paradigms:
fimaChem (enhancement of chemotherapeutics for localised treatment of cancer),
fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc
(nucleic acid therapeutics delivery).
Photochemical internalisation induces triggered endosomal release that is used
to unlock the true potential of a wide array of therapeutic modalities. The
company's lead programme fimaChem consists of a pivotal study in bile duct
cancer, an orphan indication with a high unmet need and without approved
products. fimaVacc applies a unique mode of action to enhance the essential
cytotoxic effect of therapeutic cancer vaccines, which works in synergy with
several other state-of-the-art vaccination technologies. fimaNAc utilises the
endosomal release to provide intracellular delivery of nucleic acids, such as
mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks
facing this emerging and promising field.
For further information, please visit: www.pcibiotech.com
(http://www.pcibiotech.com)
Forward-looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
PCI Biotech disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.